Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Kenneth J. Moise, Jr., MD Guest: Christopher Robinson, MD Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical. Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.

Advances in Women's Health

HDFN: New Understandings of Risk, Diagnosis, and Therapeutic Approaches

Guest: Dr. Patricia M. Boatwright, MD Ob-gyn Dr. Patricia Boatwright once cared for a patient who told her the following philosophy: "If it doesn't bother you, don't bother it." Sadly, this is far from the only isolated event in which healthcare professionals hear this or a similar mantra from their patients. To help us better manage this all-too-common occurrence, Dr. Boatwright walks us through this particular patient case and how she encourages her patients to listen to their bodies rather than their peers.

Lessons from an OB-GYN Practice: Facing Patient Fears Head On

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Anna-Barbara Moscicki, MD Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.

Riding the Wave of Change in Cervical Cancer Screening: Managing Patients in Light of Risk Using Extended Genotyping

Host: Linda Bradley In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS, SIS, and MRI for diagnosis, and nonsurgical options that can help relieve symptoms associated with these bothersome growths.

Uterine Fibroids: Focus on Medical Management

Host: Nanette F. Santoro, MD In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.

Understanding Emerging Options for Managing Vasomotor Symptoms

Host: Floor J. Backes, MD Guest: Robert L. Coleman, MD, FACOG, FACS Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon. 

Keeping Pace in Women’s Cancers: Ovarian Cancer—From IO to PARP

Host: Jack David Sobel, MD Managing complicated, recurrent vulvovaginal candidiasis (RVVC) can be, well, complicated. Join Dr. Jack Sobel for his seminal presentation on the challenges of VVC and RVVC, the role of fluconazole, and what makes RVVC so complicated. He’ll also discuss new therapies on the horizon that may finally provide the answer to achieving greater recurrence-free rates for millions of women. 

Riding the Wave of Change in Managing Vulvovaginal Candidiasis—Adapting to a New Era

Host: Eliot Brinton, MD, FAHA, FNLA Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE The latest information and guideline updates that healthcare professionals need to know for their practice are included in the recent AHA/ACC/Multisociety Blood Cholesterol Guidelines. These guidelines also introduce female-specific risk enhancers to help assess cardiovascular risk in women and discuss several new options for lowering LDL-C. Also examined is the new treatment option available for those with elevated triglyceride levels at risk of ASCVD events. The results from the REDUCE-IT trial on icosapent ethyl have led to new FDA indications and updates to many guidelines that now incorporate its use for patients with a high risk of a serious event and an elevated triglyceride level. The key takeaway from this expert dialogue is that lipid management has been redefined.

The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

Advances in Women’s Health addresses advances, breakthroughs and treatments for conditions related to women’s health, as well as preventive measures physicians can advise their patients to pursue. Topics will include breast health as it relates to cancer, ethnicity, fertility and pregnancy; osteoporosis; female athletes’ health and emotional issues; pregnancy and all facets related to it; aging; nutrition and health; eating disorders; alternative medicine; and sex education.

hubhopper

Advances in Women's Health

hubhopper